High risk Langerhans cell histiocytosis in children: the role of salvage in improving the outcome. A single center experience
Authors:
Open Access
- 24 June 2024
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-8
Abstract
Background: In pediatric multi-system high risk organs (RO +) Langerhans cell histiocytosis (LCH), failing 1st line treatment has the highest mortality. We aim to present the outcome of failure of 1st line whether due to disease progression (DP) at end of induction or reactivation (REA) after initial better status response. Patients and methods: Sixty-seven RO + LCH patients with hemopoietic, hepatic or splenic involvement, treated between 2007 and 2019 were retrospectively analyzed. The median follow-up (IQR) is 6 years (4–8.8 y).They were subjected to 2 eras of treatment; one with salvage by 2-Cda based regimen (2-CdABR) and another without. Results: Of 67 patients, M/F 40/27, median age 1.74 y (0.2–10 y), 42 failed 1st line (62.7%). Of them DP n = 22 (52%) and REA n = 20 (48%). Of those with DP, 9/22 patients received 2-CdABR, where 5 survived in better status. While the remaining 13 did not receive 2-CdABR and all of them died. Otherwise, of those with REA, 12/20 reactivated on RO + mode. Of them, 8/12 received 2-CdABR, where only one survived in better status and the remaining 4 received vinblastine-based regimen,where 2 died and 2 were rescued. RO + 5-year overall survival (OS) was 65% (CI 95% 54 -78) while the event free survival (EFS) 36% (26.3—50.1). The OS of DP 27% (14–54) versus REA 67% (49–93) p 0.004. OS of DP with 2-CdABR 56% (31–97.7) versus 8% without (2–51), p < 0.001. While OS of REA with 2-CdABR 38% (13–100) versus 74% without (53–100) p 0.7. Conclusion: Survival of RO + remains limited. Failure of 1st line in RO + due to DP carries worse prognosis in relation to REA. In DP those who were not salvaged by 2-CdABR, showed dismal outcome. This could not be shown when applied in REA.Keywords
All Related Versions
Funding Information
- 57357 Hospital
This publication has 32 references indexed in Scilit:
- Treatment of Langerhans cell histiocytosis with a modified risk‐adapted protocol—experience from a tertiary cancer institute in IndiaPediatric Blood & Cancer, 2018
- Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol StudyInternational Journal of Hematology, 2016
- Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 yearsPediatric Blood & Cancer, 2012
- Severe persistent bone marrow failure following therapy with 2‐chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brainPediatric Blood & Cancer, 2011
- Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in JapanInternational Journal of Hematology, 2010
- 2′‐chlorodeoxyadenosine (2‐CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH‐S‐98 protocol of the histiocyte societyPediatric Blood & Cancer, 2009
- Bone marrow assessment in Langerhans cell histiocytosisPediatric Blood & Cancer, 2007
- Response to initial treatment of multisystem langerhans cell histiocytosis: An important prognostic indicatorMedical and Pediatric Oncology, 2002
- Treatment of children with Langerhans cell histiocytosis with 2‐chlorodeoxyadenosineAmerican Journal of Hematology, 2002
- Natural history of histiocytosis X: A pediatric oncology group studyMedical and Pediatric Oncology, 1986